Post-transplant Lymphoproliferative Disease - 10 Studies Found
| Completed |
: Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) :
|
| Completed |
: Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy : Posttransplant Lymphoproliferative Disorder : 2014-01-20 :
|
| Not yet recruiting |
: Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant :
|
| Completed |
: Phase II of Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma :
|
| Terminated |
: Relationship Between EBV and PTLD : Pediatric Heart Transplant : 2005-09-20 |
| Terminated |
: Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation : Lymphoproliferative Disorder : 2002-04-09 : Biological: therapeutic allogeneic lymphocytes |
| Completed |
: Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder :
: |
| Terminated |
: Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation :
: 2004-07-08 :
|
| Completed |
: Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive Cluster of Differentiation(CD) 20-Positive Post-Transplant Lymphoproliferative Disorder :
|
| Active, not recruiting |
: Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation : Lymphoproliferative Disorder : 2003-08-06 :
|